Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2025	Mar. 31, 2024
Income Statement [Abstract]
Revenue		$ 828	$ 1,001
Operating expenses:
Cost of revenue		1,551	1,656
Sales and marketing		4,069	4,194
General and administrative		6,162	4,070
Amortization of acquired intangible assets		105	372
Research and development		1,428	1,501
Total operating expenses		13,315	11,793
Operating loss		(12,487)	(10,792)
Other income (expense):
Interest income		66	68
Interest expense		(9)	(12)
Change in fair value - Senior Secured Convertible Note		(14,478)	291
Debt extinguishments loss - Senior Secured Convertible Note			(167)
Other income (expense), net		(14,421)	180
Loss before provision for income tax		(26,908)	(10,612)
Provision for income taxes
Net loss attributable to Lucid Diagnostics Inc.		(26,908)	(10,612)
Less: Deemed dividend on Series A and Series A-1 Convertible Preferred Stock			(7,496)
Less: Series B Convertible Preferred Stock dividends earned		(9,110)
Net loss attributable to Lucid Diagnostics Inc. common stockholders		$ (36,018)	$ (18,108)
Net loss per share attributable to Lucid Diagnostics Inc. common stockholders - basic	[1]	$ (0.52)	$ (0.40)
Net loss per share attributable to Lucid Diagnostics Inc. common stockholders - diluted	[1]	$ (0.52)	$ (0.40)
Weighted average common shares outstanding, basic		68,796,392	45,014,410
Weighted average common shares outstanding, diluted		68,796,392	45,014,410

[1] - Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.